TLC to Present at the 42nd Annual JP Morgan Healthcare Conference
27 Dec 2023
Gene Therapy
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 27, 2023 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a late clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical needs in orthopedic disorders, today announced that the company will present at the 42nd Annual JP Morgan Healthcare Conference at 2:00pm PT on Tuesday, January 9, 2024. As a part of the APAC track, TLC will present at the Golden Gate Ballroom at the Marriott Marquis, 780 Mission Street, San Francisco.
Company management will provide updates on the status of the Company’s innovative product candidates. A live webcast will not be available. The team will also participate in 1x1s during the conference. To inquire on potential collaborations and meetings, please contact the team via the TLC (tlcbio.com) company website.
The invite-only JP Morgan Healthcare Conference has been and still is one of the largest and most influential healthcare industry events held annually for over 40 years, bringing together executives, investors, bankers, analysts, and policymakers across the biopharma, med-tech, healthcare services, and digital health sectors.
About TLC BioSciences
TLC BioSciences is a late clinical stage specialty pharmaceutical company dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in its track record, the company’s expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures. BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Latest programs include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells. Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management.
Contact Dawn Chi / Corporate Communications / dawn@tlcbio.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.